Compare Boston Scientific Corporation (BSX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Banco Santander SA — how do they compare? Boston Scientific Corporation trades at $42.71 (market cap $66.37B), while Banco Santander SA trades at $13.59 (market cap $195.40B). The key difference: Banco Santander SA is far larger — about 2.9× Boston Scientific Corporation's market cap, and Banco Santander SA pays a 2.04% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SAN | |
|---|---|---|
Market Cap | $66.37B | $195.40B |
Sector | Health | Financials |
52-Week High | $108.14 | $14.37 |
52-Week Low | $42.63 | $8.31 |
Enterprise Value | $75.94B | — |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Banco Santander (SAN) trades at $13.66, down 1.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.4144, beating expectations, and maintains a strong net income margin of 26.72%. Recent developments include the acquisition of TSB and AI-driven efficiency initiatives targeting over $1.15 billion in business value. The stock shows a P/E of 13.57 and P/B of 1.62, indicating reasonable valuation relative to peers.
The outlook for SAN is positive, supported by record profitability, strategic acquisitions, and cost-saving measures. However, risks include declining cash flows, regulatory scrutiny in Spain, and macroeconomic pressures on loan growth. Analyst consensus is bullish with 64% buy ratings, but investors should monitor execution on efficiency targets and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
